IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 372 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2019. The put-call ratio across all filers is 1.32 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $7,703,904 | +18.9% | 161,643 | +8.1% | 0.00% | 0.0% |
Q1 2024 | $6,480,304 | -17.5% | 149,488 | -3.8% | 0.00% | 0.0% |
Q4 2023 | $7,859,056 | +5.0% | 155,348 | -5.9% | 0.00% | -33.3% |
Q3 2023 | $7,485,986 | +36.8% | 165,035 | +23.8% | 0.00% | +50.0% |
Q2 2023 | $5,471,062 | +8.8% | 133,343 | -5.2% | 0.00% | 0.0% |
Q1 2023 | $5,029,262 | +4.8% | 140,718 | +10.7% | 0.00% | 0.0% |
Q4 2022 | $4,800,114 | -15.5% | 127,088 | -1.1% | 0.00% | 0.0% |
Q3 2022 | $5,682,000 | -6.4% | 128,453 | -21.7% | 0.00% | 0.0% |
Q2 2022 | $6,069,000 | +0.9% | 163,954 | +1.0% | 0.00% | 0.0% |
Q1 2022 | $6,013,000 | +24.8% | 162,318 | +2.5% | 0.00% | +100.0% |
Q4 2021 | $4,818,000 | -14.2% | 158,344 | -5.4% | 0.00% | -50.0% |
Q3 2021 | $5,616,000 | +11.9% | 167,421 | +33.0% | 0.00% | 0.0% |
Q2 2021 | $5,021,000 | -73.4% | 125,883 | -70.1% | 0.00% | -71.4% |
Q1 2021 | $18,900,000 | -28.2% | 420,377 | -9.7% | 0.01% | -30.0% |
Q4 2020 | $26,331,000 | +27.7% | 465,698 | +7.2% | 0.01% | +11.1% |
Q3 2020 | $20,617,000 | -22.8% | 434,505 | -4.1% | 0.01% | -30.8% |
Q2 2020 | $26,705,000 | +29.5% | 452,943 | +4.1% | 0.01% | +8.3% |
Q1 2020 | $20,629,000 | -16.0% | 435,038 | +7.0% | 0.01% | 0.0% |
Q4 2019 | $24,564,000 | +5.1% | 406,634 | +4.2% | 0.01% | 0.0% |
Q3 2019 | $23,372,000 | +2.2% | 390,248 | +9.7% | 0.01% | 0.0% |
Q2 2019 | $22,866,000 | +288.7% | 355,783 | +390.9% | 0.01% | +300.0% |
Q1 2019 | $5,882,000 | +54.1% | 72,477 | +2.7% | 0.00% | 0.0% |
Q4 2018 | $3,816,000 | +19.5% | 70,576 | +14.0% | 0.00% | +50.0% |
Q3 2018 | $3,193,000 | +30.1% | 61,923 | +5.2% | 0.00% | 0.0% |
Q2 2018 | $2,454,000 | -18.7% | 58,881 | -14.0% | 0.00% | 0.0% |
Q1 2018 | $3,017,000 | -9.9% | 68,452 | +2.9% | 0.00% | 0.0% |
Q4 2017 | $3,347,000 | +24.9% | 66,527 | +25.9% | 0.00% | 0.0% |
Q3 2017 | $2,679,000 | +18.4% | 52,837 | +18.8% | 0.00% | 0.0% |
Q2 2017 | $2,262,000 | +38.8% | 44,480 | +9.7% | 0.00% | +100.0% |
Q1 2017 | $1,630,000 | +161.6% | 40,536 | +211.2% | 0.00% | 0.0% |
Q4 2016 | $623,000 | +48.3% | 13,024 | +13.4% | 0.00% | – |
Q3 2016 | $420,000 | -72.2% | 11,482 | -82.3% | 0.00% | -100.0% |
Q2 2016 | $1,513,000 | -35.8% | 64,960 | +11.7% | 0.00% | -33.3% |
Q1 2016 | $2,356,000 | -11.3% | 58,181 | +35.7% | 0.00% | 0.0% |
Q4 2015 | $2,655,000 | – | 42,873 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Sicart Associates LLC | 367,360 | $14,768,000 | 10.67% |
BB BIOTECH AG | 7,461,295 | $299,944,000 | 9.81% |
TANAKA CAPITAL MANAGEMENT INC | 83,399 | $3,353,000 | 7.39% |
DOWLING & YAHNKE LLC | 675,843 | $27,169,000 | 2.89% |
Opus Point Partners Management, LLC | 78,900 | $3,172,000 | 2.35% |
Motley Fool Asset Management LLC | 259,000 | $10,412,000 | 2.25% |
ARK Investment Management | 127,563 | $5,128,000 | 1.48% |
Motley Fool Wealth Management, LLC | 325,965 | $13,104,000 | 1.26% |
PINNACLE ASSOCIATES LTD | 1,514,710 | $60,891,000 | 1.16% |
Bellevue Group AG | 205,253 | $8,251,000 | 1.10% |